OS among the patients with EGFR or ALK mutations according to treatment modality. OS, overall survival; EGFR, epidermal growth factor receptor; ALK, anaplastic lymphoma kinase; SRS, safety of stereotactic radiosurgery; WBRT, whole brain radiotherapy; CI, confidence interval.